<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492217</url>
  </required_header>
  <id_info>
    <org_study_id>UniversidadeNL</org_study_id>
    <nct_id>NCT02492217</nct_id>
  </id_info>
  <brief_title>Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients</brief_title>
  <official_title>Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Nova de Lisboa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify new candidate genes and proteins that are differentially expressed in responders'&#xD;
      vs non-responders to anti-TNF alpha therapy at the several time points the investigators will&#xD;
      use the transcriptomic and proteomic analyses. Demonstrate a link between gene expression and&#xD;
      protein markers regarding prediction to anti-TNF alpha therapy efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">May 28, 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response biomarkers (Assessment of Spondyloarthritis International Society (ASAS) 20 and Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>14 weeks</time_frame>
    <description>To identify anti-TNF alpha clinical response biomarkers by microarrays and proteomics technology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL evaluation</measure>
    <time_frame>14 weeks</time_frame>
    <description>To evaluate quality of life using ASQOL and SF-36 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI progression</measure>
    <time_frame>14 weeks</time_frame>
    <description>Rachis evaluation according to acute and structural lesions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AS according to Portuguese Society of Rheumatology (SPR) guidelines (1984 modified New&#xD;
             York Criteria, but allowing the use of MRI as imagiological criteria)&#xD;
&#xD;
          -  Patient enrolment followed national guidelines for TNF antagonist use for the&#xD;
             treatment of AS&#xD;
&#xD;
          -  Adults between 18 to 75 years&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Corticosteroid therapy allowed (equivalent to ≤ 10 mg prednisone) and / or&#xD;
             NSAID(nonsteroidal antiinflammatory drug), stable dose in 4 weeks before study&#xD;
             initiation&#xD;
&#xD;
          -  Adequate contraception (barrier or hormonal) in men and women of childbearing age&#xD;
             (patients and their partners&#xD;
&#xD;
          -  Adequate renal and hepatic function (2 times ULN)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy or breastfeeding&#xD;
&#xD;
          -  Previous treatment with biologic DMARD's (disease-modifying antirheumatic drug)&#xD;
&#xD;
          -  Intraarticular injections or infiltrations of extraaxial joints and tendons within 28&#xD;
             days before or at screening, or intraarticular injections of sacroiliac joints ≤ 28&#xD;
             days before screening&#xD;
&#xD;
          -  History of rheumatic disorder other than AS&#xD;
&#xD;
          -  Other forms of spondylarthritis than AS&#xD;
&#xD;
          -  Any uncontrolled medical condition (e.g., uncontrolled diabetes mellitus, unstable&#xD;
             ischemic heart disease)&#xD;
&#xD;
          -  History or signs of demyelinating disease&#xD;
&#xD;
          -  Malignancy (except for completely treated squamous or basal cell carcinoma)&#xD;
&#xD;
          -  Moderate to severe heart failure (NYHA class III/IV) Positive serology for hepatitis&#xD;
             B, hepatitis C, or human immunodeficiency virus&#xD;
&#xD;
          -  Active or latent tuberculosis (TB) or histoplasmosis or other severe infections such&#xD;
             as sepsis, and opportunistic infections&#xD;
&#xD;
          -  Infections requiring hospitalization or intravenous treatment with antibiotics within&#xD;
             30 days or oral treatment with antibiotics within 14 days before enrollment&#xD;
&#xD;
          -  Ankylosis of the spine (syndesmophytes presence at all levels from D12 to S1 in X-ray&#xD;
             (XR) lateral view)&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando M. Pimentel-Santos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NOVA Medical School/Faculdade de Ciências Médicas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaime C. Branco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOVA Medical School/Faculdade de Ciências Médicas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculdade de Ciências Médicas da Universidade Nova de Lisboa</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 3, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing Spondylitis</keyword>
  <keyword>adalimumab</keyword>
  <keyword>TNF-alpha agents</keyword>
  <keyword>spondyloarthritis</keyword>
  <keyword>biologic therapies</keyword>
  <keyword>AS</keyword>
  <keyword>biomarkers</keyword>
  <keyword>efficacy prediction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

